These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38042376)

  • 1. Dynamic immuno-nanomedicines in oncology.
    Ling H; Zhang Q; Luo Q; Ouyang D; He Z; Sun J; Sun M
    J Control Release; 2024 Jan; 365():668-687. PubMed ID: 38042376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLAN B for immunotherapy: Promoting and leveraging anti-tumor B cell immunity.
    Shi Y
    J Control Release; 2021 Nov; 339():156-163. PubMed ID: 34563591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies.
    Altun I; Demirlenk YM; Atar D; Cevik E; Gunduz S; Albadawi H; Oklu R
    J Vasc Interv Radiol; 2024 Feb; 35(2):164-172. PubMed ID: 38272636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.
    Ji B; Wei M; Yang B
    Theranostics; 2022; 12(1):434-458. PubMed ID: 34987658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Immunoediting in the Era of Immuno-oncology.
    Gubin MM; Vesely MD
    Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
    Zhang M; Kim JA; Huang AY
    Front Immunol; 2018; 9():341. PubMed ID: 29535722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermal immuno-nanomedicine in cancer.
    Yang Z; Gao D; Zhao J; Yang G; Guo M; Wang Y; Ren X; Kim JS; Jin L; Tian Z; Zhang X
    Nat Rev Clin Oncol; 2023 Feb; 20(2):116-134. PubMed ID: 36604531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles as immunomodulators and translational agents in brain tumors.
    Grippin AJ; Dyson KA; Qdaisat S; McGuiness J; Wummer B; Mitchell DA; Mendez-Gomez HR; Sayour EJ
    J Neurooncol; 2021 Jan; 151(1):29-39. PubMed ID: 32757093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditioning neoadjuvant therapies for improved immunotherapy of cancer.
    Benson Z; Manjili SH; Habibi M; Guruli G; Toor AA; Payne KK; Manjili MH
    Biochem Pharmacol; 2017 Dec; 145():12-17. PubMed ID: 28803721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.